Seoyoun Jeong

Seoyoun Jeong

Auto-generated profile, based on publicly available information

Seoyoun Jeong

Department of Anatomy and Cell Biology, Seoul National University College of Medicine, 103, Daehak-ro, Jongno-gu, Seoul, 03080, Korea (the Republic of)

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2024 in Anatomy & Cell Biology
Verified
Journal Article
Open access
PDF file
TATomoyo Agura
Tomoyo Agura
SSSeulgi Shin
Seulgi Shin
HJHyejung Jo
Hyejung Jo
SJSeoyoun Jeong
Seoyoun Jeong
HAHyovin Ahn
Hyovin Ahn
Jae Seung KangJae Seung Kang
Jae Seung Kang
Tomoyo Agura, Seulgi Shin, Hyejung Jo, Seoyoun Jeong, Hyovin Ahn, So Young Pang, June Lee, Jeong-Ho Park, Yejin Kim, Jae Seung Kang. Anat Cell Biol -0001;0:. https://doi.org/10.5115/acb.24.120

17 March 2026 in Nanotechnology
Verified
Journal Article
Open access
SJSeoyoun Jeong
Seoyoun Jeong
SSSeulgi Shin
Seulgi Shin
HJHyejung Jo
Hyejung Jo
YKYejin Kim
Yejin Kim
Jae Seung KangJae Seung Kang
Jae Seung Kang
This study explores the potential of porous silicon nanoparticles (pSiNPs) as advanced nanocarriers to enhance the therapeutic efficacy and reduce the cytotoxicity of niclosamide for COVID-19 treatment. Niclosamide, an FDA-approved drug used to treat tapeworm infections, has been suggensted as a potential treatment for COVID-19. However, its clinical application is limited by its significant cytotoxicity and low bioavailability. To address these challenges, three types of pSiNPs-pSiNP-H, pSiNP-COOH, and pSiNP-NH 2 -were synthesized. Niclosamide was successfully loaded onto each type of pSiNPs, achieving a loading efficiency over 30%. Among them, the antiviral activity of niclosamide-loaded pSiNP-NH 2 was assessed against the Delta variant of SARS-CoV-2 in Vero E6 cells using plaque assays and real-time PCR. Results demonstrated that niclosamide-loaded pSiNP-NH 2 significantly suppressed viral replication more efficiently than free niclosamide at equivalent doses, while minimizing host cell cytotoxicity. These findings suggest that pSiNP-NH 2 could serve as a potent drug delivery platform, improving the therapeutic index of niclosamide for COVID-19 treatment.